Comparative Evaluation of Efficacy, Safety and Haemostatic Parameters of Enoxaparin and Fondaparinux in Unstable Coronary Artery Disease
Aim: To compare the safety and efficacy of Enoxaparin (EX) and Fondaparinux (FD) in patients with Unstable Coronary Artery Disease (UCAD). Materials and Methods: A prospective, open label, randomized comparative study was designed to study the comparative efficacy and safety of EX and FD in UCA...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
JCDR Research and Publications Private Limited
2014-01-01
|
Series: | Journal of Clinical and Diagnostic Research |
Subjects: | |
Online Access: | https://jcdr.net/articles/PDF/3908/10-6359_E(C)_F(T)_PF1(MH)_PFA(H)_PFA(Ak)_PF2(RKH).pdf |
Summary: | Aim: To compare the safety and efficacy of Enoxaparin (EX) and
Fondaparinux (FD) in patients with Unstable Coronary Artery
Disease (UCAD).
Materials and Methods: A prospective, open label, randomized
comparative study was designed to study the comparative efficacy
and safety of EX and FD in UCAD patients. Recovery, recurrence,
major and minor bleeding and biochemical investigations were
evaluated and compared among two arms.
Results: The baseline demographic characteristics were similar
in both groups, with mean age of 56.05 and 56.05 years in EX
and FD group respectively. Recovery was equal in two arms.
Recurrent MI or angina was seen numerically more in EX group,
but it did not statistically vary from that in the FD group. Incidence
of haemorrhage was similar in both groups at 9 days, but at
30 days, EX showed a higher incidence (p<0.05). Deaths were
prevented in both the treatment arms. Bleeding parameters such
as BT, CT and platelet count were not altered in both groups.
Conclusion: FD appeared to be better than EX in efficacy, as
was indicated by a numerically more decrease in recurrence of
angina or MI. FD regimen group also had better safety profile, as
there was no incidence of haemorrhage at 30 days Therefore,
we conclude that FD is an attractive option than EX in UCAD
patients. |
---|---|
ISSN: | 2249-782X 0973-709X |